|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00674141 |
|
Date of registration:
|
06/05/2008 |
|
Primary sponsor: |
|
|
Public title:
|
Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment
|
|
Scientific title:
|
Nasal Administration of Dexamethasone for MS Treatment |
|
Date of first enrolment:
|
July 2008 |
|
Target sample size:
|
10 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
http://clinicaltrials.gov/show/NCT00674141 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Israel
| | | | | | | |
|
Contacts
|
|
Name:
|
Elka Touitou, PhD, Prof. |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Hebrew University, Jerusalem. Israel |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- MS patients with esatblished relapsing remitting attacks
- increase in EDSS of at least 1 point for a least one day
Exclusion Criteria:
- children under 18
- pregnant patients
- patients with diabetes
- known allergy to steroids
- patients who received steroids within 3 months prior to the study
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
MS Patient With Relpasing Remitting Attacks
|
|
Intervention(s)
|
|
Drug: Dexamethasone soduim phosphate
|
|
Primary Outcome(s)
|
|
reduction in the EDSS functional system score
[Time Frame: four months]
|
|
Secondary ID(s)
|
|
MS089-HMO-CTIL
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|